Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 11;11(6):1546.
doi: 10.3390/jcm11061546.

Characteristics and Outcomes of COVID-19-Related Hospitalization among PLWH

Roberta Gagliardini  1 , Alessandra Vergori  1 , Patrizia Lorenzini  1 , Stefania Cicalini  1 , Carmela Pinnetti  1 , Valentina Mazzotta  1 , Annalisa Mondi  1 , Ilaria Mastrorosa  1 , Marta Camici  1 , Simone Lanini  1 , Marisa Fusto  1 , Jessica Paulicelli  1 , Maria Maddalena Plazzi  1 , Luisa Marchioni  1 , Chiara Agrati  1 , Anna Rosa Garbuglia  1 , Pierluca Piselli  1 , Emanuele Nicastri  1 , Fabrizio Taglietti  1 , Fabrizio Palmieri  1 , Gianpiero D'Offizi  1 , Enrico Girardi  1 , Francesco Vaia  1 , Andrea Antinori  1
Affiliations

Characteristics and Outcomes of COVID-19-Related Hospitalization among PLWH

Roberta Gagliardini et al. J Clin Med. .

Abstract

Background: There is conflicting evidence for how HIV influences COVID-19 infection. The aim of this study was to compare characteristics at presentation and the clinical outcomes of people living with HIV (PLWH) versus HIV-negative patients (non-PLWH) hospitalized with COVID-19. Methods: Primary endpoint: time until invasive ventilation/death. Secondary endpoints: time until ventilation/death, time until symptoms resolution. Results: A total of 1647 hospitalized patients were included (43 (2.6%) PLWH, 1604 non-PLWH). PLWH were younger (55 vs. 61 years) and less likely to be with PaO2/FiO2 < 300 mmHg compared with non-PLWH. Among PLWH, nadir of CD4 was 185 (75−322) cells/μL; CD4 at COVID-19 diagnosis was 272 cells/μL (127−468) and 77% of these were virologically suppressed. The cumulative probability of invasive mechanical ventilation/death at day 15 was 4.7% (95%CI 1.2−17.3) in PLWH versus 18.9% (16.9−21.1) in non-PLWH (p = 0.023). The cumulative probability of non-invasive/invasive ventilation/death at day 15 was 20.9% (11.5−36.4) in PLWH versus 37.6% (35.1−40.2) in non-PLWH (p = 0.044). The adjusted hazard ratio (aHR) of invasive mechanical ventilation/death of PLWH was 0.49 (95% CI 0.12−1.96, p = 0.310) versus non-PLWH; similarly, aHR of non-invasive/invasive ventilation/death of PLWH was 1.03 (95% CI 0.53−2.00, p = 0.926). Conclusion: A less-severe presentation of COVID-19 at hospitalization was observed in PLWH compared to non-PLWH; no difference in clinical outcomes could be detected.

Keywords: COVID-19; HIV; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

R.G. received institutional grant from Gilead Sciences, personal fees for consultancy from Janssen-Cilag, M.S.D., Gilead, Viiv and Theratechnologies; A.V. received institutional grant from Gilead Sciences, personal fees for consultancy and travel grant from Janssen-Cilag, speaker’s fee from M.S.D.; S.C. received personal fees for consultancy from Janssen-Cilag, M.S.D., Gilead and Viiv; C.P. received travel grants and honoraria from Gilead and Janssen-Cilag; A.M. received honoraria from Gilead Sciences and Viiv Healthcare; E.N. received training fee and medical board from Gilead Science, S.O.B.I., Eli Lilly and Roche; EG received grants from Gilead e Mylan, speakers fee from Gilead; A.A. received personal fees for consultancy from Janssen-Cilag, M.S.D., Gilead, GlaxoSmithKline, Theratechnologies, Roche and Viiv. The other authors have nothing to declare.

References

    1. Blanco J.L. Correspondence COVID-19 in patients with HIV: Clinical case series. Lancet HIV. 2020;7:e314–e316. doi: 10.1016/S2352-3018(20)30111-9. - DOI - PMC - PubMed
    1. Gervasoni C., Meraviglia P., Riva A., Giacomelli A., Oreni L., Minisci D., Atzori C., Ridolfo A., Cattaneo D. Clinical features and outcomes of HIV patients with coronavirus disease 2019. Clin. Infect. Dis. 2020;71:2276–2278. doi: 10.1093/cid/ciaa579. - DOI - PMC - PubMed
    1. Karmen-Tuohy S., Carlucci P.M., Zervou F.N., Zacharioudakis I.M., Rebick G., Klein E., Reich J., Jones S., Rahimian J. Outcomes Among HIV-Positive Patients Hospitalized With COVID-19. J. Acquir. Immune Defic. Syndr. 2020;85:6–10. doi: 10.1097/QAI.0000000000002423. - DOI - PMC - PubMed
    1. Sigel K., Swartz T., Golden E., Paranjpe I., Somani S., Richter F., De Freitas J.K., Miotto R., Zhao S., Polak P., et al. Coronavirus 2019 and People Living with Human Immunodeficiency Virus: Outcomes for Hospitalized Patients in New York City. Clin. Infect. Dis. 2020;10029:2933–2938. doi: 10.1093/cid/ciaa880. - DOI - PMC - PubMed
    1. Shalev N., Scherer M., LaSota E.D., Antoniou P., Yin M.T., Zucker J., Sobieszczyk M.E. Clinical Characteristics and Outcomes in People Living With Human Immunodeficiency Virus Hospitalized for Coronavirus Disease 2019. Clin. Infect. Dis. 2020;24:2294–2297. doi: 10.1093/cid/ciaa635. - DOI - PMC - PubMed